Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib in BRCA-mutated pancreatic cancer
NCT02042378Phase 2Completed
- Sponsor
- pharma&
- Start
- Apr 2014
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of rucaparib in pancreatic ductal adenocarcinoma (PDAC), sponsored by pharma&. Primary endpoint: Overall Response Rate. Started Apr 2014; status: completed.
02
Drugs
rucaparib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02042378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042378.